Daniel Einhorn
Endocrinology, Diabetes & Metabolism · la Jolla, CANPI 1275525776
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $467,869 of the $578,406 with a category attached, or 80.9%. 24 manufacturers reported payments, led by Novo Nordisk at 29.5% of the total. Reporting peaked in 2021 at $215,103 and has fallen 99.4% since, to $1,218 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 548 payments — averaging $1055.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$171K
- Lilly USA, LLC$139K
- Abbott$84K
- Intuity Medical Inc$58K
- Corcept Therapeutics$45K
- Johnson & Johnson$24K
- plus $58K from 18 others
What the payments were for
- Consulting fees$83,80314%
- Speaking & faculty fees$467,86981%
- Travel & lodging$20,3844%
- Food & beverage$6,2851%
- Education$60%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 128 | $170,701 |
| Lilly USA, LLC | 175 | $139,080 |
| Abbott | 66 | $83,869 |
| Intuity Medical Inc | 7 | $57,812 |
| Corcept Therapeutics | 26 | $45,193 |
| Johnson & Johnson | 69 | $23,608 |
| Boehringer Ingelheim | 19 | $15,492 |
| Sanofi-aventis U.S. LLC | 16 | $14,565 |
| Eli Lilly | 2 | $5,250 |
| AstraZeneca | 6 | $5,070 |
| Vistapharm, Inc. | 5 | $4,250 |
| Senseonics, Incorporated | 2 | $3,523 |
| Lifescan, Inc. | 4 | $2,732 |
| Janssen Scientific Affairs, LLC | 3 | $2,642 |
| Zealand Pharma US, Inc. | 4 | $2,389 |
| Bayer | 1 | $1,535 |
| Esperion Therapeutics, Inc. | 3 | $284 |
| Amgen(2 entities) | 4 | $195 |
| Janssen Global Services, LLC | 2 | $67 |
| Mannkind Corporation | 1 | $59 |
| Insulet Corporation | 2 | $41 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $20 |
| Gilead | 1 | $16 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBELSUS$81,997
- FreeStyle Libre Pro$80,009
- JARDIANCE$73,641
- BAQSIMI$60,558
- Pogo Automatic Blood Glucose Monitoring System$57,750
- Korlym$44,983
- Ozempic$40,831
- INVOKANA$23,107
- Victoza$14,730
- SOLIQUA 100/33$11,883
- LYUMJEV$10,500
- Tresiba$10,228
- FARXIGA$4,958
- Thyquidity$4,250
- FreeStyle Libre 2$3,619
- Eversense$3,500
- OneTouch$2,661
- TOUJEO$2,618
- XARELTO$2,500
- ZEGALOGUE$2,389
How this compares
$578,406 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Other endocrinology, diabetes & metabolism in la Jolla
- Athena Philis-Tsimikasla Jolla$574K
- Matthew Levinela Jolla$134K
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.